Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeu
(NQ:
ALDX
)
5.340
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Aldeyra Therapeu
< Previous
1
2
3
4
5
Next >
Recap: Aldeyra Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 01, 2023
Via
Benzinga
The Week In Charts: 0DTE Options - Too Good To Be True?
April 30, 2023
Zero-days; how Core Methodology can be used in Crypto, with current Crypto and stock market conditions; favorite stock picks.
Via
Talk Markets
Short Volatility Alert: Aldeyra Therapeutics
April 28, 2023
On Thursday, shares of Aldeyra Therapeutics (NASDAQ: ALDX) experienced volatile short activity. After the activity, the stock price went down -0.22% to $9.05. The overall sentiment for ALDX has been...
Via
Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).
Via
Benzinga
Chart Of The Day: Aldeyra - Skyrocketing
April 11, 2023
Revenue is expected to grow by 2,045.80% next year. Earnings are estimated to increase by 16.90% next year and continue to compound at an annual rate of 73.70% for the next 5 years.
Via
Talk Markets
Earnings Outlook For Aldeyra Therapeutics
March 08, 2023
Via
Benzinga
Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
October 06, 2022
Via
Benzinga
Recap: Aldeyra Therapeutics Q2 Earnings
August 05, 2022
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...
Via
Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
March 27, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session
March 24, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
March 23, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial
July 12, 2022
Via
Benzinga
Why Aldeyra Therapeutics' Shares Are Soaring Today?
June 08, 2022
Via
Benzinga
Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients
February 28, 2023
Via
Benzinga
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
February 23, 2023
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...
Via
Benzinga
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication
December 13, 2022
Via
Benzinga
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
September 14, 2022
Via
Benzinga
$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying
August 08, 2022
Although US stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Aldeyra Therapeutics: Q1 Earnings Insights
May 05, 2022
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For August 5, 2022
August 05, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
Via
Benzinga
Earnings Outlook For Aldeyra Therapeutics
August 04, 2022
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Aldeyra...
Via
Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
July 13, 2022
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 12, 2022
Via
Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
July 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 12, 2022
Via
Benzinga
Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness
May 18, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.